01—Abstract
Summary
Summary of the 10-Q filed August 6, 2025. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc (RPRX) reported a second quarter 2025 10-Q covering the period ended June 30, 2025.
Consolidated net income was $90.6 milliona for the quarter, compared with $194.4 million in the second quarter of 2024, and net income attributable to Royalty Pharma plc was $30.2 million, versus $102.0 million a year earlier. Results were driven by a $300.5 million R&D funding expense (primarily an upfront $250.0 million payment for daraxonrasib royalties), a $92.5 million provision for credit losses on the Revolution Medicines funding commitments, and $45.7 million... more precisely, $91.0 million of quarterly share-based compensation tied largely to the Internalization. Total income and other revenues rose to $578.7 million from $537.3 million, and the company recorded a $203.9 million provision benefit from changes in expected cash flows.
The company completed the Internalization on May 16, 2025, acquiring its former external manager, RP Management, LLC. The filing reports goodwill of $924.6 millionb, a $380 million term loan assumed, and a total purchase price of $565.2 million. Going forward, the company no longer pays Operating and Personnel Payments to the legacy manager, but G&A expenses rose sharply, and share-based compensation for 22.8 million unvested RP Holdings Class E Interests is expected to be recognized over five to nine years.
Capital deployment was heavy: the company repurchased 31.2 million Class A shares for about $1.0 billionc in the first six months of 2025, leaving roughly $2.0 billion under its authorization. Cash and cash equivalents fell to $631.9 million from $929.0 million at year-end 2024, and total borrowings reached $8.2 billion in principal.
Portfolio Receipts rose 19.7% to $727.5 milliond in the quarter, and Vertex's cystic fibrosis franchise remained the largest revenue contributor at 35% of total income and other revenues. The company also disclosed that Vertex did not remit the full amount of royalties on Alyftrek net sales in the second quarter, and it has started dispute resolution procedures.
02—Key points
Key Highlights
- Net income attributable to Royalty Pharma plc was $30.2 million in Q2 2025, down from $102.0 million in Q2 2024; six-month figure was $268.5 million versus $106.8 million.
- Internalization completed May 16, 2025: goodwill of $924.6 million recorded, a $380 million term loan assumed, and total purchase price of $565.2 million.
- Share-based compensation of $91.0 million in Q2 2025, including $44.1 million for RP Holdings Class E Interests and $45.7 million for Employee EPAs.
- Repurchased 31.2 million Class A ordinary shares for approximately $1.0 billion in the first six months of 2025; about $2.0 billion remains under the authorization.
- Portfolio Receipts increased 19.7% to $727.5 million in Q2 2025, with Royalty Receipts up 11.0% to $671.7 million.
- Acquired daraxonrasib royalty with a $250.0 million upfront payment and entered a up to $2 billion Revolution Medicines funding arrangement, resulting in a $92.5 million credit loss provision.
- Vertex accounted for 35% of total income and other revenues in Q2 2025, and the company has commenced dispute resolution over Alyftrek royalties not fully paid in the quarter.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 6, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $578.66M$537.27M | +7.7% |
| R&D Expenses | $300.50M$500K | +60000.0% |
| Operating Expenses | $368.87M$267.64M | +37.8% |
| Operating Income | $209.80M$269.63M | −22.2% |
| Net Income | $32.18M$102.00M | −68.5% |
| EPS (Basic) | $0.08$0.23 | −65.2% |
| EPS (Diluted) | $0.07$0.23 | −69.6% |
| Shares Outstanding (Basic) | 423.51M451.02M | −6.1% |
| Shares Outstanding (Diluted) | 562.30M596.91M | −5.8% |
05—Questions
Frequently Asked Questions
Why did net income fall so sharply in the second quarter of 2025?
Net income attributable to Royalty Pharma plc fell to $30.2 million from $102.0 million. Key drivers included $300.5 million of R&D funding expense, $179.8 million of G&A expenses (including about $91.0 million of share-based compensation and $15.0 million of acquisition-related costs), a $92.5 million provision for credit losses on unfunded commitments, and $27.4 million of losses on available-for-sale debt securities. These were partly offset by a $203.9 million provision benefit for changes in expected cash flows from financial royalty assets.
What changed in the company's structure after the Internalization?
Royalty Pharma acquired RP Manager on May 16, 2025, ending its external management arrangement with RP Management, LLC. The company no longer pays Operating and Personnel Payments, which were 6.5% of royalty cash receipts plus 0.25% of security investments. Employees now work directly for Royalty Pharma, LLC, and employee compensation has become the largest component of G&A expenses.
How much capital did the company return to shareholders, and what remains available?
In the first six months of 2025, the company repurchased 31.2 million Class A ordinary shares at a cost of about $1.0 billion and paid dividends of $188.7 million ($0.22 per share in each of two quarterly payments). Approximately $2.0 billion remained available under the new $3.0 billion repurchase program as of June 30, 2025, which expires June 23, 2027.
What is the company's debt position?
Total borrowings were $8.2 billion in principal as of June 30, 2025, consisting of $7.8 billion of senior unsecured notes and a $380 million term loan due July 2027. The company also has up to $1.8 billion of undrawn revolving commitments and states that it was in compliance with its financial covenants as of June 30, 2025.
What risks are highlighted in the filing?
The filing notes that Vertex did not remit the full amount of royalties on Alyftrek net sales in the second quarter of 2025, and the company has begun dispute resolution procedures. Vertex accounted for 35% of total income and other revenues. The filing also flags the volatility of GAAP results from the effective interest method, the remaining $711.4 million of unrecognized Class E share-based compensation, and pending regulatory and litigation matters.
06—Continue